pluri-biotech.com (PLUR) Company Long-Term Loans and Borrowings

Pluri - graphic logo of issuer PLUR

Pluri Inc. (PLUR) is a pioneer in cell therapy, developing biologics from placental tissues using 3D cultivation for muscle regeneration. This large-scale living tissue synthesis technology effectively combats radiation exposure and inflammation. The market value dynamics of the asset with the 0.00 indicator are illustrated below. Growth prospects rely on the transition to commercial licensing and cost optimization within metabolic programs.

PLUR Pluristem Therapeutics: Company Long-Term Debts in the range 04/28/2023 - 10/29/2026

Pluri - analytical breakdowns and key metrics (PLUR)

- price and consensus price forecast:
Stock Price Pluristem Therapeutics|PLUR - Price Target Chart
- market capitalization data:
Market Value Pluri|PLUR - Total Company Value
- book capitalization data:
Accounting Value per Share Pluri|PLUR - Book Capitalization|Market Capitalization to Book Value Ratio pluri-biotech.com|PLUR - Cumulative Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Pluri Inc.|PLUR - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Pluristem Therapeutics|PLUR - Company Aggregate Debts|Debts to Book Value Pluri|PLUR - Company Long-Term Liabilities|Amount of Current Liabilities Pluri
Fundamental valuation:PLUR - Pluri Inc.
Manufactured products of Pluri Inc

This metric reflects the total volume of Pluri Inc. (PLUR) obligations with a maturity of more than one year, allowing for an assessment of the credit structure's stability and the cost of capital servicing. By analyzing changes in the company's long-term debt, an investor determines the firm's financial cushion, which is critically important for the biotechnology sector amid geopolitical instability in the Middle East and the risks of supply chain disruptions.

Competitors of Pluri Inc.

ascendispharma.com - Company Long-Term Debts|Company Long-Term Debt Madrigal Pharmaceuticals, Inc. (MDGL)|CORT: Company Long-Term Loans and Borrowings|RYTM (Rhythm Pharmaceuticals Inc) - Company Long-Term Debt|Akero Corp (AKRO) - Company Long-Term Liabilities|MTSR (Metsera Inc) - Company Long-Term Debts|Company Long-Term Debts moonlaketx.com (MLTX)|Crinetics (CRNX) - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings NAMS (NewAmsterdam Pharma Company)|Soleno - Company Long-Term Debt|Company Long-Term Liabilities Amicus Corp FOLD|ETNB (89bio, Inc.) - Company Long-Term Debts|agios.com (AGIO) - Long-Term Debt|GPCR - Company Long-Term Liabilities|MiMedx Group Inc (MDXG) - Amount of Long-Term Liabilities|RZLT (Rezolute Corp) - Company Long-Term Debts|Company Long-Term Debts Lexicon Corp|Company Long-Term Debts MBX Biosciences Inc (MBX)|Company Long-Term Debt ALT (altimmune.com)|AARD: Company Long-Term Debt|Sagimet Biosciences, Inc. - Long-Term Debt|BIOA - Company Long-Term Debt|BMEA - Company Long-Term Debt|quincetx.com - Company Long-Term Debts|GUTS (fractyl.com) - Long-Term Debt Volume|VTVT: Company Long-Term Debt|Long-Term Debt Volume ATPC|Company Long-Term Debt SYBX (Synlogic, Inc.)|Company Long-Term Liabilities LPCN (Lipocine Corporation)|Matinas BioPharma Holdings (MTNB) - Company Long-Term Debt|Spruce Biosciences Inc. - Long-Term Liabilities|GLTO - Company Long-Term Debt|Carmell Corp. (CTCX) - Company Long-Term Debt|LUMO: Company Long-Term Liabilities|ONVO (Organovo Corp) - Company Long-Term Debts|RDUS - Company Long-Term Debt